Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner
K. K. Mahadevan, K. McAndrews, V. LeBleu, S. Yang, H. Lyu, B. Li, A. M. Sockwell, M. L. Kirtley, S. J. Morse, B. M. Moreno Diaz, M. P. Kim, N. Feng, A. M. Lopez, P. A. Guerrero, H. Sugimoto, , R. Kalluri
This study shows that MRTX1133, a KrasG12D inhibitor, reduces early pancreatic lesions and, when combined with immunotherapy, regresses advanced PDAC by enhancing CD8+ T cell activity.
bioRxiv · Feb 15, 2023 · PreprintCancer Biology